The gist of a new report predicting pharma's key numbers for 2017? Big changes in biotech and pharma of late—and pitfalls ahead—but the usual giants still…
A former Bayer exec sued the company, claiming she was wrongfully terminated after she stood up for a pregnant colleague.
Endo’s new CEO is making his presence felt. He's engineering a move away from Endo's once-core pain franchise, cutting 375 sales reps and staffers in…
The Trump administration is considering a far-outside-the-box candidate to lead the FDA in tech capitalist Jim O’Neill, Bloomberg reports.
Any drugmakers still thinking they got off easy when Donald Trump won the U.S. presidential election may want to think again.
When Eli Lilly set aside its Alzheimer’s prospect solanezumab, it also put a set of sales jobs on the chopping block.
Celgene’s breast cancer med Abraxane turned up “encouraging” results in a chemo-combo trial. But that’s as far as the research will go.
Amgen’s betting it can raise awareness of multiple myeloma by sharing stories—and to do so, it’s enlisting the pros.
What's a pharma to do to keep new meds moving to market? Sell off as many of the old ones as possible, if the current trend is any clue—and Novartis has…
Newly bulked up by M&A, Mylan plans to cut a chunk of its workforce—perhaps up to 3,500 jobs—as it moves to retrench and refocus.